KR950703002A - T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN - Google Patents

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN Download PDF

Info

Publication number
KR950703002A
KR950703002A KR1019950700587A KR19950700587A KR950703002A KR 950703002 A KR950703002 A KR 950703002A KR 1019950700587 A KR1019950700587 A KR 1019950700587A KR 19950700587 A KR19950700587 A KR 19950700587A KR 950703002 A KR950703002 A KR 950703002A
Authority
KR
South Korea
Prior art keywords
seq
lol
peptide
individual
allergens
Prior art date
Application number
KR1019950700587A
Other languages
Korean (ko)
Other versions
KR100455023B1 (en
Inventor
브루스 크녹스 로버트
비르 싱 모한
롤란드 제니퍼
블라헤르 벨라
슈피오글루 센크
Original Assignee
제임스 바일돈 포터
더 유니버시티 오브 멜버른(The University Of Melbourne)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 바일돈 포터, 더 유니버시티 오브 멜버른(The University Of Melbourne) filed Critical 제임스 바일돈 포터
Publication of KR950703002A publication Critical patent/KR950703002A/en
Application granted granted Critical
Publication of KR100455023B1 publication Critical patent/KR100455023B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 롤륨 페렌(Loliume perenne)종의 주요 단백질 알레르겐인 Lol pV의 단리된 펩타이드를 제공한다. 본 발명의 범주내의 치료 펩타이드는 Lol pV의 단백질 알레르겐의 적어도 하나의 T세포 에피토프, 또는 바람직하게는 적어도 두개의 T세포 에피토프를 포함한다. 본 발명은 또한 대응 천연 알레르겐 또는 그의 부분과 유사한 또는 향상된 치료성질을 가지나, 감소된 부작용을 갖는 변형된 펩타이드를 제공한다. 본 발명은 추가로 본 발명의 펩타이드를 암호화하는 핵산서열을 제공한다. 본 발명은 추가로 본 발명의 펩타이드를 암호화하는 핵산서열을 제공한다. 개인에 있어서, Lol pV 또는 Lol pV에 면역학적으로 관련된 알레르겐에 대한 미감성의 치료 또는 진단방법, 본 발명의 하나이상의 펩타이드를 포함하는 치료조성물이 또한 제공된다.The present invention provides an isolated peptide of Lol pV, which is a major protein allergen of Lolium perenne species. Therapeutic peptides within the scope of the present invention comprise at least one T cell epitope, or preferably at least two T cell epitopes, of the protein allergen of Lol pV. The present invention also provides modified peptides having similar or improved therapeutic properties to the corresponding natural allergens or portions thereof, but with reduced side effects. The present invention further provides nucleic acid sequences encoding the peptides of the present invention. The present invention further provides nucleic acid sequences encoding the peptides of the present invention. In an individual, there is also provided a method of treating or diagnosing aesthetics for Lol pV or an allergen immunologically related to Lol pV, a therapeutic composition comprising one or more peptides of the invention.

Description

독보리 꽃가루 알레르겐의 T-세포 에피토프(T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN)T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 cDNA 클론 12R(SEQ IR No : 1)의 뉴클레오티드 서열 및 그의 예상된 아미노산 서열(SEQ IR No : 2). 클론 12R은 Lol pV의 완전한 길이 클론이다.1 shows the nucleotide sequence of cDNA clone 12R (SEQ IR No: 1) and its expected amino acid sequence (SEQ IR No: 2). Clone 12R is a full length clone of Lol pV.

제2도는 Lol pV로 부터 유도된 다양한 길이의 본 발명의 다양한 펩타이드.2 shows various peptides of the invention of various lengths derived from Lol pV.

제3도는 유도 알레르겐 Lol pV, 조(crude)목초 꽃가루 추출물 또는 조 버뮤다 그래스(Bermuda grass)꽃가루 추출물의 존재하에서 자기조직 조사된 PBMC로 배양된 T-세포 라인의 34일째로 부터의 T-세포의 자극 지수, [3H]TdR 압입에 의해 평가되고 증식의 그래프. 그 결과는 알레르겐을 갖는 세포의 평균 CPM을 배지만 같는 세포의 평균 CPM으로 나누어서 결정된 자극지수를 표현되고, 각 알레르겐 농도는 삼중으로 시험된다.FIG. 3 shows T-cells from day 34 of T-cell lines cultured with autologously irradiated PBMCs in the presence of induced allergen Lol pV, crude herb pollen extract or crude Bermuda grass pollen extract. Stimulation index, assessed by [3H] TdR indentation and graph of proliferation. The result is a stimulation index determined by dividing the mean CPM of cells with allergens by the mean CPM of the same cells, and each allergen concentration is tested in triplicate.

제4도는 Lol pV 합성 펩타이드에 대한, 건강한 독보리 꽃가루 알레르기성 성인으로 부터 유도된, 45일째 T-세포 라인의 증식 반응의 그래프, 그 결과는 복제 배양물의 분당 평균 계수(counts)로서 표현되고 알레르겐의 결여시에 세포의 배경반응은 4894 CPM이다. 펩타이드의 농도는 10㎍/m1이었다.FIG. 4 is a graph of the proliferative response of T-cell lines at 45 days, derived from healthy single barley pollen allergic adults, to Lol pV synthetic peptide, the results of which are expressed as mean counts per minute of replicate cultures In the absence the background response of the cell is 4894 CPM. The concentration of peptide was 10 μg / m1.

제5도는 Lol pV 합성 펩타이드에 대한, T세포 클론 A12의 증식반응의 그래프 그 결과는 복제 배양물의 분당 평균 계수(CPM)로 표현되고, 알레르겐의 부재상태의 세포의 배경반응이 358CPM이고 Y-측은 로그 스케일로 나타난다. 펩타이드의 농도는 10㎍/ml이었다.FIG. 5 is a graph of the proliferative response of T cell clone A12 to Lol pV synthetic peptide and the results are expressed as the mean counts per minute (CPM) of the replication culture, with the background response of the cells in the absence of allergens being 358 CPM and Appears on a log scale. The concentration of peptide was 10 μg / ml.

제6도는 Lol PV합성 펩타이드에 대한, 건강한 독보리 꽃가루 알레르기성 성인으로 부터 유도된 제2T-세포라인의 증식 반응의 그래프. 그 결과는 분당 평균 계수(CPU)로서 표현되고, 알레르겐의 부재시의 세포의 배경 반응이 2,500CPM이고, 펩타이드의 농도는 0.1㎍/ml이다.FIG. 6 is a graph of the proliferative response of 2T-cell lines induced from healthy single barley pollen allergic adults to Lol PV synthetic peptide. The results are expressed as mean counts per minute (CPU), the background response of the cells in the absence of allergens is 2,500 CPM, and the concentration of peptide is 0.1 μg / ml.

Claims (36)

펩타이드 1(SEQ ID NO : 3), 6(SEQ ID NO : 8), 7(SEQ ID NO : 9), 14(SEQ ID NO : 16), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 21(SEQ ID NO : 23), 22(SEQ ID NO : 24), 23(SEQ ID NO : 25), 24(SEQ ID NO : 26), 25(SEQ ID NO : 27), 28(SEQ ID NO : 30), 30(SEQ ID NO : 32), 33(SEQ ID NO : 35) 및 34(SEQ ID NO : 36). 제2도에 나타난 바와 같은 아미노산 서열들로 구성되는 그룹으로 부터 선택된 아미노산 서열을 포함하는, Lol pV 또는 그의 동족체의 단리된 펩타이드.Peptide 1 (SEQ ID NO: 3), 6 (SEQ ID NO: 8), 7 (SEQ ID NO: 9), 14 (SEQ ID NO: 16), 16 (SEQ ID NO: 18), 19 (SEQ ID NO: 21, 21 (SEQ ID NO: 23), 22 (SEQ ID NO: 24), 23 (SEQ ID NO: 25), 24 (SEQ ID NO: 26), 25 (SEQ ID NO: 27), 28 (SEQ ID NO: 30), 30 (SEQ ID NO: 32), 33 (SEQ ID NO: 35), and 34 (SEQ ID NO: 36). An isolated peptide of Lol pV or its homologue, comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in FIG. 제1항에 있어서, Lol pV 적어도 하나의 T세포 에피토프를 포함하고, 펩타이드 6(SEQ ID NO : 8), 7(SEQ ID NO : 9), 12(SEQ ID NO : 14), 14(SEQ ID NO : 16), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27), 28(SEQ ID NO : 30), 33(SEQ ID NO : 35) 및 34(SEQ ID NO : 36). 제2도에 나타난바와 같은 아미노산 서열들로 구성되는 그룹으로 부터 선택된 아미노산 서열을 포함하는 단리된 펩타이드.The method of claim 1, comprising Lol pV at least one T cell epitope and comprising peptides 6 (SEQ ID NO: 8), 7 (SEQ ID NO: 9), 12 (SEQ ID NO: 14), 14 (SEQ ID NO: 16), 16 (SEQ ID NO: 18), 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27), 28 (SEQ ID NO: 30), 33 (SEQ ID NO: 35) and 34 (SEQ ID NO: 36). An isolated peptide comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in FIG. 제1항에 있어서, Lol pV 적어도 하나의 B세포 에피토프를 포함하고, 1(SEQ ID NO : 3), 7(SEQ ID NO : 9), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 21(SEQ ID NO : 23), 23(SEQ ID NO : 25), 24(SEQ ID NO : 26), 28(SEQ ID NO : 30), 30(SEQ ID NO : 32) and 34(SEQ ID NO : 36). 의 제2도에 나타난 바와같은 아미노산 서열들로 구성되는 그룹으로 부터 선택된 아미노산 서열을 포함하는, 단리된 펩타이드.The method of claim 1, wherein the Lol pV comprises at least one B cell epitope, wherein 1 (SEQ ID NO: 3), 7 (SEQ ID NO: 9), 16 (SEQ ID NO: 18), 19 (SEQ ID NO). : 21), 21 (SEQ ID NO: 23), 23 (SEQ ID NO: 25), 24 (SEQ ID NO: 26), 28 (SEQ ID NO: 30), 30 (SEQ ID NO: 32) and 34 (SEQ ID NO: 36). An isolated peptide comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in FIG. 제2항에 있어서, 적오도 2.0의 T세포 자극지수를 갖는 단리된 펩타이드의 일부분.The portion of the isolated peptide of claim 2 having a T cell stimulation index of equatorial 2.0. 제2항에 있어서, 제4도 또는 제6도에 나타난 바와 같은 펩타이드의 T세포 자극지수와 같거나 그보다 큰 T세포 자극지수를 갖는 단리된 펩타이드의 일부분.The portion of the isolated peptide of claim 2 having a T cell stimulation index equal to or greater than the T cell stimulation index of the peptide as shown in FIG. 4 or 6. 제2항에 있어서, Lol pV 알레르겐에 민감한 개인에게 투여된 때, 개인에게서 T세포 아네르기를 유도하거나, 개인에게서 T세포의 림프킨 분비 프로파일을 변형시키는 단리된 펩타이드.The isolated peptide of claim 2, which when administered to an individual susceptible to Lol pV allergen, induces T cell anergic in the individual or modifies the lymphocyte secretion profile of T cells in the individual. 제2항에 있어서, Lol pV에 민감한 개인의 실질적 %로 Lol pV에 특이한 면역 글로부린과 결합하지 않거나, 상기 면역 글로부린에 펩타이드 또는 그의 부분에 결합하는 경우, 이러한 결합은 Lol pV에 민감한 개인의 실질적으로 %로 비만세포 또는 호염기성 세포로 부터 중재자의 방출을 가져오지 않는 단리된 펩타이드.3. The method of claim 2, wherein in a substantial percentage of individuals who are sensitive to Lol pV do not bind to immunoglobulins specific to Lol pV, or when binding to a peptide or portion thereof to the immunoglobulin, the binding is substantially in an individual of Lol pV sensitive individuals. An isolated peptide that does not result in release of mediators from mast cells or basophils in%. 제2항에 있어서, 정제된 본래의 Lol pV가 면역 글로부린 E에 결합하는 정도보다 실질적으로 덜한 정도로 면역 글로부린 E에 결합하는 단리된 펩타이드.The isolated peptide of claim 2, wherein the purified native Lol pV binds to immunoglobulin E to a degree substantially less than that of immunoglobulin E. 제1항의 펩타이드를 암호하는 서열을 갖는 단리된 핵산 서열.An isolated nucleic acid sequence having a sequence encoding the peptide of claim 1. 제1항의 펩타이드를 암호하는 핵산서열의 기능적 동등물.Functional equivalent of the nucleic acid sequence encoding the peptide of claim 1. 제2항의 펩타이드와 반응성인 T세포와 면역학적으로 교차 반응성인 단리된 펩타이드.An isolated peptide immunologically cross reactive with T cells reactive with the peptide of claim 2. 적어도 2.2의 T세포 자극 지수를 갖는 Lol pV 또는 그의 동족체의 단리된 펩타이드.Isolated peptide of Lol pV or its analogs having a T cell stimulation index of at least 2.2. 제12항에 있어서, T세포 자극지수가 적어도 3.0인 단리된 펩타이드.The isolated peptide of claim 12, wherein the T cell stimulation index is at least 3.0. 제1항의 변형된 펩타이드.The modified peptide of claim 1. 제2항의 변형된 펩타이드.The modified peptide of claim 2. Lol pV에 민감한 개인의 실질적 %로 Lol pV에 특이한 면역 글로부린 E와 결합하지 않거나, 상기 면역 글로부린 E에 결합이 일어나는 경우, 이러한 결합은 Lol pV에 개인의 실질적 %로 비반 세포 또는 호염기성 세포로 부터 중재자의 방출을 가져오지 않는 변형된 펩타이드.If a substantial percentage of individuals susceptible to Lol pV do not bind to immunoglobulin E specific to Lol pV, or if binding occurs to the immunoglobulin E, this binding results in substantial percentage of individuals to Lol pV from apoptotic or basophilic cells. Modified peptides that do not result in the release of mediators. 제14항에 있어서, Lol pV에 민감한 개인에게 투여됐을 때 Lol pV 알레르겐에 대한 개인의 알레르기 반응을 변형시키는 변형된 펩타이드.The modified peptide of claim 14, which modifies an individual's allergic response to Lol pV allergens when administered to an individual sensitive to Lol pV. 제1항의 펩타이드와 특이 반응성인 모노클로날 항체.Monoclonal antibodies that are specifically reactive with the peptide of claim 1. 제9항의 핵산으로 형질 전환된 숙주세포에서 생성된 단리된 펩타이드.An isolated peptide produced in a host cell transformed with the nucleic acid of claim 9. 제10항의 핵산으로 형질전환된 숙주세포에서 생성된 단리된 펩타이드.An isolated peptide produced in a host cell transformed with the nucleic acid of claim 10. 제1항의 펩타이드를 암호화하는 핵산 서열을 포함하는 발현 벡터.An expression vector comprising a nucleic acid sequence encoding the peptide of claim 1. 제1항의 펩타아드를 암호화하는 서열의 기능적 동등물을 포함하는 발현벡터.An expression vector comprising a functional equivalent of the sequence encoding the peptad of claim 1. 적어도 하나의 제2항의 단리된 펩타이드와 약제학적으로 허용가능한 담체 또는 희석제를 포함하는 치료 조성물.A therapeutic composition comprising at least one isolated peptide of claim 2 and a pharmaceutically acceptable carrier or diluent. 제15항의 적어도 하나의 단리된 펩타이드와 약제학적으로 허용가능한 담체 또는 희석제를 포함하는 치료 조성물.A therapeutic composition comprising at least one isolated peptide of claim 15 and a pharmaceutically acceptable carrier or diluent. 개인에 있어서, Lol pV 알레르겐 또는 Lol pV 알레르겐과 면역학적으로 교차 반응성인 알레르겐에 대한 민감성을 치료하기 위한 약제의 제조를 위한 제23항 또는 제24항에 따른 조성물의 용도.Use of a composition according to claim 23 or 24 for the manufacture of a medicament for treating a sensitivity to an Lol pV allergen or an allergen immunologically cross-reactive with the Lol pV allergen. 제23항 또는 제24항에 따른 조성물의 치료 효과량을 개인에게 투여하는 것을 포함하는 Lol pV 알레르겐 또는 Lol pV 알레르겐과 면역학적으로 교차 반응성인 알레르겐에 대한 민감성 치료방법.A method of treating sensitivity to an allergen immunologically cross-reactive with a Lol pV allergen or Lol pV allergen, comprising administering to a individual a therapeutically effective amount of the composition of claim 23. 혈액성분과 펩타이드의 결합에 적절한 조건하에서 제1항에 따른 적어도 하나의 펩타이드와 개인으로 부터 얻을 혈액 샘플을 혼합하는 것을 포함하는 개인에 있어서, Lol pV에 대한 민감성 검출방법.A method for detecting sensitivity to Lol pV in an individual comprising mixing a blood sample obtained from the individual with at least one peptide according to claim 1 under conditions suitable for binding the blood component and the peptide. 제27항에 있어서, 결합이 일어나는 정도가 B세포 작용, T세포 작용, T세포 증식 또는 T세포 작용과 B세포 증식의 조합을 평가하여 결정되는 방법.The method of claim 27, wherein the extent to which binding occurs is determined by evaluating B cell action, T cell action, T cell proliferation, or a combination of T cell action and B cell proliferation. 제23항 또는 제24항에 있어서, 개인에 있어서, 독보리 꽃가루 알레르겐과 면역학적으로 교차 반응성인 Lol PV 알레르겐에 대한 민감증을 치료하기 위한 약제의 제조를 위한 제23항 또는 제24항에 따른 적어도 두 조성물의 용도.25. The method according to claim 23 or 24, wherein in an individual, at least according to claim 23 or 24 for the manufacture of a medicament for the treatment of sensitivity to Lol PV allergens immunologically cross-reactive with poisonous pollen allergens. Use of two compositions. 제23항 또는 제24항의 적어도 두 조성물의 치료 효과량을 개인에게 동시에 또는 순서적으로 투여하는 것을 포함하는, 개인에 있어서 Lol pV 또는 독보리 꽃가루 알레르겐과 면역학적으로 교차 반응성인 Lol pV 알레르겐에 대한 민감성 치료 방법.25. Sensitivity to Lol pV allergens immunologically cross-reactive with Lol pV or poisonous pollen allergens in an individual, comprising simultaneously or sequentially administering to the individual a therapeutically effective amount of at least two compositions of claims 23 or 24 Method of treatment. 펩타이드 6(SEQ ID NO : 8), 7(SEQ ID NO : 9), 12(SEQ ID NO : 14), 14(SEQ ID NO : 16), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27), 28(SEQ ID NO : 30), 33(SEQ ID NO : 35) and 34(SEQ ID NO : 36).으로 부터 구성되는 그룹으로 부터 선택된 적어도 두개의 Lol pV 펩타이드와 약제학적으로 허용가능한 담체를 포함하고, Lol pV 에 민감한 개인에 조성물의 투여시, 개인의 T세포가 Lol pV에 대해 내성화되도록 Lol pV 의 T세포 에피토프의 충분한 %를 포함하는 치료조성물.Peptide 6 (SEQ ID NO: 8), 7 (SEQ ID NO: 9), 12 (SEQ ID NO: 14), 14 (SEQ ID NO: 16), 16 (SEQ ID NO: 18), 19 (SEQ ID NO: 21, 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27), 28 (SEQ ID NO: 30), 33 (SEQ ID NO: 35) and 34 (SEQ ID NO: 36). Lol pV comprising at least two Lol pV peptides selected from the group consisting of: and a pharmaceutically acceptable carrier, the T cells of the individual being resistant to Lol pV upon administration of the composition to an individual sensitive to Lol pV. A therapeutic composition comprising a sufficient percentage of the T cell epitopes of. 제23항에 있어서, 14(SEQ ID NO : 16) 및 22(SEQ ID NO : 24); 14(SEQ ID NO : 16) 및 25(SEQ ID NO : 27); 19(SEQ ID NO : 21) 및 22(SEQ ID NO : 24); 19(SEQ ID NO : 21) 및 25(SEQ ID NO : 27); 14(SEQ ID NO : 16), 22(SEQ ID NO : 24), 및 25(SEQ ID NO : 27); 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 및 25(SEQ ID NO : 27); 14(SEQ ID NO : 16), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27) 및 34(SEQ ID NO : 36); 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27) 및 34(SEQ ID NO : 36); 14(SEQ ID NO : 16), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24) 및 25(SEQ ID NO : 27); 14(SEQ ID NO : 16), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27), 및 34(SEQ ID NO : 36); 6(SEQ ID NO : 8), 7(SEQ ID NO : 9), 9(SEQ ID NO : 11), 12(SEQ ID NO : 14), 14(SEQ ID NO : 16), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27), 33(SEQ ID NO : 35) 및 34(SEQ ID NO : 36); 6(SEQ ID NO : 8), 9(SEQ ID NO : 11), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 및 34(SEQ ID NO : 36); 및 6(SEQ ID NO : 8), 9(SEQ ID NO : 11), 14(SEQ ID NO : 16), 16(SEQ ID NO : 18), 19(SEQ ID NO : 21), 22(SEQ ID NO : 24), 25(SEQ ID NO : 27) 및 34(SEQ ID NO : 36)으로 구성되는 그룹으로 부터 선택된 펩타이드들의 한 조합을 포함하는 조성물.25. The method of claim 23 further comprising: 14 (SEQ ID NO: 16) and 22 (SEQ ID NO: 24); 14 (SEQ ID NO: 16) and 25 (SEQ ID NO: 27); 19 (SEQ ID NO: 21) and 22 (SEQ ID NO: 24); 19 (SEQ ID NO: 21) and 25 (SEQ ID NO: 27); 14 (SEQ ID NO: 16), 22 (SEQ ID NO: 24), and 25 (SEQ ID NO: 27); 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), and 25 (SEQ ID NO: 27); 14 (SEQ ID NO: 16), 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27) and 34 (SEQ ID NO: 36); 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27) and 34 (SEQ ID NO: 36); 14 (SEQ ID NO: 16), 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24) and 25 (SEQ ID NO: 27); 14 (SEQ ID NO: 16), 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27), and 34 (SEQ ID NO: 36); 6 (SEQ ID NO: 8), 7 (SEQ ID NO: 9), 9 (SEQ ID NO: 11), 12 (SEQ ID NO: 14), 14 (SEQ ID NO: 16), 16 (SEQ ID NO : 18), 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), 25 (SEQ ID NO: 27), 33 (SEQ ID NO: 35) and 34 (SEQ ID NO: 36); 6 (SEQ ID NO: 8), 9 (SEQ ID NO: 11), 16 (SEQ ID NO: 18), 19 (SEQ ID NO: 21), 22 (SEQ ID NO: 24), and 34 (SEQ ID NO: 36); And 6 (SEQ ID NO: 8), 9 (SEQ ID NO: 11), 14 (SEQ ID NO: 16), 16 (SEQ ID NO: 18), 19 (SEQ ID NO: 21), 22 (SEQ ID A composition comprising a combination of peptides selected from the group consisting of NO: 24), 25 (SEQ ID NO: 27) and 34 (SEQ ID NO: 36). 개인에게 투여하는 것을 포함하는, Lol pV 알레르겐 또는 Lol pV 알레르겐과 면역학적으로 교차 반응성인 알레르겐에 대한 민감성을 치료하기 위한 약재의 제조를 위한 제31항 또는 제32항의 조성물의 용도.Use of the composition of claim 31 or 32 for the manufacture of a medicament for the treatment of sensitivity to Lol pV allergens or allergens immunologically cross-reactive with Lol pV allergens. 제32항의 치료조성물의 개인에게 투여하는 것을 포함하는 개인에 있어서 Lol pV 알레르겐 또는 Lol pV 알레르겐과 교차 반응성인 알레르겐에 대한 민감성 치료 방법,A method of treating sensitivity to allergens cross-reactive with Lol pV allergens or Lol pV allergens in an individual comprising administering to the individual of the therapeutic composition of claim 32, 제5항의 변형된 펩타이드.The modified peptide of claim 5. 제42항의 적어도 하나의 단리된 펩타이드를 포함하는 치료조성물.The therapeutic composition comprising at least one isolated peptide of claim 42. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950700587A 1992-08-14 1993-08-13 T-cell Epitope of Taraxacum Pollen Allergens KR100455023B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93006092A 1992-08-14 1992-08-14
US07/930060 1992-08-14
US07/930,060 1992-08-14
PCT/AU1993/000415 WO1994004564A1 (en) 1992-08-14 1993-08-13 T cell epitopes of ryegrass pollen allergen

Publications (2)

Publication Number Publication Date
KR950703002A true KR950703002A (en) 1995-08-23
KR100455023B1 KR100455023B1 (en) 2005-04-20

Family

ID=25458872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700587A KR100455023B1 (en) 1992-08-14 1993-08-13 T-cell Epitope of Taraxacum Pollen Allergens

Country Status (11)

Country Link
EP (1) EP0656012B1 (en)
JP (1) JP3868480B2 (en)
KR (1) KR100455023B1 (en)
AT (1) ATE283281T1 (en)
AU (1) AU679455B2 (en)
CA (1) CA2142370C (en)
DE (1) DE69333709T2 (en)
FI (1) FI115827B (en)
NO (1) NO320873B1 (en)
NZ (2) NZ254688A (en)
WO (1) WO1994004564A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710126A (en) * 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
NZ271818A (en) * 1993-08-13 1997-11-24 Immulogic Pharma Corp T cell epitopes of ryegrass pollen antigen
US7112333B1 (en) 1994-08-05 2006-09-26 Heska Corporation T cell epitopes of ryegrass pollen allergen
EP0941250A1 (en) * 1996-11-04 1999-09-15 Human Genome Sciences HUMAN BLUE-LIGHT PHOTORECEPTOR hCRY2
DE19713001A1 (en) 1997-03-27 1998-10-01 Merck Patent Gmbh Gramina pollen allergen mutants for specific immunotherapy, their production and use
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
AUPR779201A0 (en) * 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
AUPS148202A0 (en) * 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
PL2393830T3 (en) 2009-02-05 2015-07-31 Circassia Ltd Grass peptides for vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340729C (en) * 1988-03-23 1999-09-07 Mohan Bir Singh Ryegrass pollen allergen
AU659509B2 (en) * 1988-03-23 1995-05-18 University Of Melbourne, The Ryegrass pollen allergen
ATE159546T1 (en) * 1990-08-17 1997-11-15 Univ Melbourne ALLERGENS FROM RYE CHUP POLLEN
JPH06509941A (en) * 1991-08-16 1994-11-10 ザ ユニバーシティ オブ メルボルン Barley pollen allergen

Also Published As

Publication number Publication date
DE69333709D1 (en) 2004-12-30
EP0656012B1 (en) 2004-11-24
AU679455B2 (en) 1997-07-03
WO1994004564A1 (en) 1994-03-03
NO320873B1 (en) 2006-02-06
ATE283281T1 (en) 2004-12-15
EP0656012A1 (en) 1995-06-07
JPH08500349A (en) 1996-01-16
JP3868480B2 (en) 2007-01-17
NO950526D0 (en) 1995-02-13
CA2142370A1 (en) 1994-03-03
FI115827B (en) 2005-07-29
DE69333709T2 (en) 2006-05-11
FI950602A0 (en) 1995-02-10
EP0656012A4 (en) 1997-04-23
KR100455023B1 (en) 2005-04-20
NZ254688A (en) 1997-11-24
FI950602A (en) 1995-02-10
NO950526L (en) 1995-04-11
AU4691693A (en) 1994-03-15
CA2142370C (en) 2008-07-15
NZ328940A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
Roebber et al. Immunochemical and genetic studies of Amb. t. V (Ra5G), an Ra5 homologue from giant ragweed pollen.
King et al. Isolation and characterization of allergens from ragweed pollen. IV
Esch et al. Isolation and characterization of a major cross-reactive grass group I allergenic determinant
Ioppolo et al. Immunological responses to antigen B from Echinococcus granulosus cyst fluid in hydatid patients
Obispo et al. The main allergen of Olea europaea (Ole e I) is also present in other species of the Oleaceae family
Fränken et al. Identification of alpha-amylase inhibitor as a major allergen of wheat flour
Britton et al. Immunoreactivity of a 70 kD protein purified from Mycobacterium bovis Bacillus Calmette-Guerin by monoclonal antibody affinity chromatography.
Ansari et al. Immunochemical studies of Lolium perenne (rye grass) pollen allergens, Lol p I, II, and III.
AU657915B2 (en) Transfer factor and methods of use
KR100328112B1 (en) Vaccine Compositions and Methods Useful for Inducing Immune Protection Against Rheumatoid Arthritis Hospital-Related Articulating Peptides
Yano et al. Purification and properties of allergenic proteins in buckwheat seeds
Calabozo et al. Purification and characterization of the main allergen of Plantago lanceolata pollen, Pla l 1
Cottam et al. Physicochemical and immunochemical characterization of allergenic proteins from rye-grass (Lolium perenne) pollen prepared by a rapid and efficient purification method
KR950703002A (en) T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN
Healy et al. Purification and biochemical analysis of antigen-specific suppressor factors obtained from the supernatant, membrane, or cytosol of a T cell hybridoma.
Hahn et al. H‐2‐linked genetic control of antibody response to soluble calf skin collagen in mice
CA2049921C (en) Allergenic proteins from ragweed and uses therefor
Aucouturier et al. Jacalin: a new laboratory tool in immunochemistry and cellular immunology
Hiller et al. Mapping of an allergenically important determinant of grass group I allergens
Wheat et al. Antigenic domains of the sperm-specific lactate dehydrogenase C4, isozyme
Ayuso et al. Isolation by mAb based affinity chromatography of two Par j I isoallergens. Comparison of their physicochemical, immunochemical and allergenic properties
Fahlbusch et al. Purification and characterization of the major allergen from apple and its allergenic cross-reactivity with Bet v 1
US6335020B1 (en) Allergenic peptides from ragweed pollen
Ansari et al. An investigation of human immune response to perennial ryegrass (Lolium perenne) pollen cytochrome c (Lol p X)
Schuurman et al. Mouse/human chimeric IgGl and IgG4 antibodies directed to the house dust mite allergen Der p 2: use in quantification of allergen specific IgG

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120928

Year of fee payment: 9

EXPY Expiration of term